The island’s effective management of the pandemic has helped boost its attractiveness as a destination for international healthcare companies to conduct clinical trials of new drugs. But to remain competitive post-COVID, Taiwan may need to take some additional steps. Within the global healthcare industry, one of the areas in which the COVID-19 pandemic has had…
The COVID-19 pandemic has presented Taiwan with a unique opportunity to gain a lead in the Asia-Pacific’s new drug discovery sector. But for Taiwan to excel, the biomedical industry is calling for a change of policies. Taiwan has been striving for many years to position itself as a regional biomedical hub and an attractive location…
AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…
Should the current target-expenditure system be extended? When the Taiwan government five years ago was working on how to revamp the National Health Insurance (NHI) program to help ensure its long-term sustainability, one of the new measures it adopted was a suggestion from the pharmaceutical industry that had been broached in AmCham Taipei’s 2010 Taiwan…
Companies have been punished for disseminating disease-awareness information. In Taiwan, as in the rest of the world with the lone exceptions of the United States and New Zealand, pharmaceutical companies are prohibited from advertising prescription drugs directly to consumers. The main rationale for that approach is the belief that decisions on what drug to prescribe…
